Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.74 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 12/20 | 0.67 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852574 | 1.00 | PIM1 (0.74) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL9570682 | 0.88 | PIM1 (0.78) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL9570687 | 0.88 | PIM1 (0.78) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL2544389 | 0.87 | PIM1 (0.76) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL2544390 | 0.87 | PIM1 (0.76) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL2544373 | 0.85 | PIM1 (1.00) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL10272939 | 0.85 | PIM1 (0.74) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL2544367 | 0.85 | PIM1 (1.00) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL9212605 | 0.85 | PIM1 (0.74) | PIM1PIM2HPGDCISD1MAOA | |
| SCHEMBL9803954 | 0.85 | PIM1 (0.74) | PIM1PIM2HPGDCISD1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159463-A1 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-07-21 | — | — | US | claimed |
| EP-1189583-B1 | INDOLE DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2005-07-20 | — | — | EP | claimed |
| US-7355054-B2 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2008-04-08 | — | — | US | disclosed |
| US-20050159463-A1 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-07-21 | — | — | US | disclosed |
| EP-1189583-B1 | INDOLE DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2005-07-20 | — | — | EP | disclosed |
| US-6858642-B1 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159463-A1 | Indole derivatives | IDO1, IDO2, H1-0 | PIM1 3614/4885PIM2 3451/4885HPGD 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.